Pharmacokinetic modeling optimizes inhibition of the ‘undruggable’ EWS-FLI1 transcription factor in Ewing Sarcoma-Reference-Cited by-同舟云学术

Pharmacokinetic modeling optimizes inhibition of the ‘undruggable’ EWS-FLI1 transcription factor in Ewing Sarcoma

Published:2013-11-11 Issue:2 Volume:5 Page:338-350
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Hong Sung-Hyeok¹,Youbi Sarah. E.¹,Hong S. Peter²,Kallakury Bhaskar³,Monroe Phillip²,Erkizan Hayriye V¹,Barber-Rotenberg Julie S.¹,Houghton Peter⁴,Üren Aykut¹,Toretsky Jeffrey A.¹

Affiliation:

1. Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA

2. Battelle Memorial Institute, Health and Life Sciences, Columbus, OH, USA

3. Department of Pathology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA

4. Nationwide Children's Research Institute, Center for Childhood Cancer, Columbus, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma;Journal of Clinical Oncology;2024-07-02

2. First Report of Cercospora citrullina Causing Spot Disease on Watermelon in China;Plant Disease;2023-10-01

3. Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer;International Journal of Biological Sciences;2023

4. Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives;Cancers;2022-05-22

5. Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma;2021-03-04